外周血NLR、TrxR表达对卵巢癌免疫治疗患者预后的评估价值  

Prognostic value of peripheral blood NLR and TrxR expression in ovarian cancer patients receiving immunotherapy

作　　者：金秋妹 曹晓莉 顾益凤 张小霞 李玉杰 JIN Qiumei;CAO Xiaoli;GU Yifeng;ZHANG Xiaoxia;LI Yujie(Department of Clinical Laboratory,Tumor Hospital Affiliated to Nantong University/Nantong Tumor Hospital,Nantong,Jiangsu 226361,China;Department of Clinical Laboratory,the First Affiliated Hospital of Anhui Medical University,Hefei,Anhui 230000,China)

机构地区：[1]南通大学附属肿瘤医院/南通市肿瘤医院检验科,江苏南通226361 [2]安徽医科大学第一附属医院检验科,安徽合肥230000

出　　处：《国际检验医学杂志》2025年第6期714-718,共5页International Journal of Laboratory Medicine

基　　金：2022年度南通市卫生健康委员会科研项目(MSZ2022030)。

摘　　要：目的探讨外周血中性粒细胞与淋巴细胞比值(NLR)、硫氧还蛋白还原酶(TrxR)在卵巢癌免疫治疗患者预后中的评估价值。方法选取2021年1月至2021年12月于南通大学附属肿瘤医院治疗的109例中晚期卵巢癌患者为研究对象。检测免疫治疗前外周血NLR、TrxR水平,探讨接受免疫治疗的卵巢癌患者NLR、TrxR对短期疗效、无进展生存期(PFS)、总生存期(OS)的评估价值。结果TrxR、NLR最佳临界值分别为4.97 U/mL、2.49%,根据TrxR、NLR最佳临界值分为TrxR高水平组69例(≥4.97 U/mL)和TrxR低水平组40例(<4.97 U/mL),NLR高水平组72例(≥2.49%)和NLR低水平组37例(<2.49%)。NLR高水平组客观缓解率(ORR)低于NLR低水平组(P<0.05),疾病进展率(DPR)高于NLR低水平组(P<0.05)。TrxR高水平组ORR低于Tr xR低水平组(P<0.05),DPR高于TrxR低水平组(P<0.05)。NLR高水平组的中位PFS为15.0个月,中位OS为16.0个月;NLR低水平组的中位PFS为19.0个月,中位OS为21.0个月。TrxR高水平组的中位PFS为15.0个月,中位OS为17.0个月;TrxR低水平组的中位PFS为18.0个月,中位OS为21.0个月。NLR、TrxR为卵巢癌免疫治疗患者PFS、OS的影响因素(P<0.05)。结论外周血NLR、TrxR水平可作为中晚期卵巢癌患者接受免疫治疗预后的重要预测指标,NLR、TrxR水平越低,卵巢癌患者预后越好。Objective To investigate the prognostic value of peripheral blood neutrophil-lymphocyte ratio(NLR)and thioredoxin reductase(TrxR)in patients with ovarian cancer receiving immunotherapy.Methods A total of 109 patients with advanced ovarian cancer treated in the Tumor Hospital Affiliated to Nantong University from January 2021 to December 2021 were selected as the research objects.The levels of NLR and TrxR in peripheral blood before immunotherapy were detected,and the evaluation value of NLR and TrxR on short-term efficacy,progression-free survival(PFS)and overall survival(OS)in ovarian cancer patients receiving immunotherapy was explored.Results The optimal cut-off values of TrxR and NLR were 4.97 U/mL and 2.49%,respectively.According to the optimal cut-off value of TrxR and NLR,the patients were divided into the high level of TrxR group(69 cases,≥4.97 U/mL)and the low level of TrxR group(40 cases,<4.97 U/mL),the high level of NLR group(72 cases,≥2.49%)and the low level of NLR group(37 cases,<2.49%).The objective response rate(ORR)of the high level of NLR group was lower than that of the low level NLR group(P<0.05),and the disease progression rate(DPR)was higher than that of the low NLR group(P<0.05).The high level of TrxR group had a significantly lower ORR and a significantly higher DPR than the low level of TrxR group(P<0.05).The median PFS and OS of the high level of NLR group were 15.0 months and 16.0 months,respectively.The median PFS and OS of the low level of NLR group were 19.0 months and 21.0 months,respectively.The median PFS and OS of the high level of TrxR group were 15.0 months and 17.0 months,respectively.The median PFS was 18.0 months and the median OS was 21.0 months in the low level of TrxR group.NLR and TrxR were the influencing factors of PFS and OS in patients with ovarian cancer immunotherapy(P<0.05).Conclusion The levels of NLR and TrxR in peripheral blood can be used as important prognostic indicators for advanced ovarian cancer patients receiving immunotherapy.The lower the levels of

关 键 词：中性粒细胞与淋巴细胞比值 硫氧还蛋白还原酶 卵巢癌 免疫治疗 无进展生存期 

分 类 号：R737.31[医药卫生—肿瘤]